942399-20-4
| Name | Amiselimod(MT-1303) free base |
| CAS | 942399-20-4 |
| Molecular Formula | C19H30F3NO3 |
| MDL Number | MFCD28902248 |
| Molecular Weight | 377.44 |
| MOL File | 942399-20-4.mol |
Synonyms
MT-1303
Novexatin
Amiselimod
Amiselimmod,MT-1303
Amiselimod, MT-1303
Amiselimod(MT-1303) free base
MT-1303;MT1303;MT 1303;AMISELIMOD
2-amino-2-(4-(heptyloxy)-3-(trifluoromethyl)phenethyl)propane-1,3-diol
2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol
2-amino-2-{2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl}propane-1,3-diol
1,3-Propanediol, 2-amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-
Hazard Information
Uses
Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases[1][2][3][4].
in vivo
Amiselimod (1 mg/kg, p.o.,) converts into Amiselimod-P which is lower in rat heart tissue than fingolimod-P, potentially contributing to the minimal cardiac effects [1].
Amiselimod (0.3-30 mg/kg, p.o., with a 6 day interval between vehicle and 0.3 mg/kg, 13 or 14 day intervals between dose levels of 0.3, 3 and 30 mg/kg) hydrochloride does not affect heart rate or ECG parameters in monkeys[1].
Amiselimod (0.3 mg/kg, p.o., daily, 3 days) decreases S1P1 expression on CD4+ T cells from mesenteric lymph nodes in C57BL/6 mice[3].
.
Amiselimod (0.3 mg/kg, p.o., daily, 28 days) inhibits the development of colitis induced by adoptive transfer of CD4+CD45RBhigh T cells in SCID mice[3].
Amiselimod (0.3 mg/kg, p.o., daily, 3-4 weeks) reduces infiltration of Th1 and Th17 cells into the colon of colitis mic e induced by adoptive transfer of CD4+CD45RBhigh T cells [3].
Amiselimod (0.1-0.3 mg/kg, p.o., daily, 21 days) inhibits the development of chronic colitis with an efficacy comparable to that of an anti-mTNF-α mAb (250 μg/mouse) in adoptive transfer of CD4+CD45RBhigh T cells induced colitis mice[3].
Amiselimod (0.1-1 mg/kg, p.o., daily, 18 weeks) strongly inhibits the development of lupus nephritis in MRL/lpr mice[4].
Amiselimod (0.1-0.3 mg/kg, p.o., daily, 10 weeks) prevents progression of lupus nephritis in NZBWF1 Mice[4].
Amiselimod (0.3 mg/kg, p.o., daily, 13 weeks) reduces infiltration of T Cells into the kidneys of NZBWF1 mice[4].
| Animal Model: | Four male cynomolgus monkeys, Macaca fascicularis, 3-4 years old [1]. |
| Dosage: | 0.3, 3, 30 mg/kg |
| Administration: | p.o., with a 6 day interval between vehicle and 0.3 mg/kg, 13 or 14 day intervals between dose levels of 0.3, 3 and 30 mg/kg. |
| Result: | Had no effects on heart rate or ECG parameters, including PR interval, QRS duration, QT interval and QTc at
doses up to 30 mg/kg Did not affect blood pressure at doses up to 30 mg/kg. |
| Animal Model: | Male C57BL/6 mice, aged 5 weeks[3]. |
| Dosage: | 0.3 mg/kg |
| Administration: | p.o., daily, 3 days |
| Result: | Decreased S1P1 expression on CD4+ T cells from mesenteric lymph nodes. |
| Animal Model: | Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice[3]. |
| Dosage: | 0.1, 0.3 mg/kg |
| Administration: | p.o., daily, 28 days |
| Result: | Body weight remained higher than that in the control group from 4 days after cell transfer. Body weight in the 0.3 mg/kg treated group was significantly higher than that in the control group from 17 days. Clinical scores (sum of scores for hunching, wasting, colon thickening, and stool consistency) in the 0.1 and 0.3 mg/kg treated groups were 1.5 and 1.1. Reduced inflammatory cell infiltrates, epithelial hyperplasia and mucin depletion from goblet cells in the colon at 0.3 mg/kg. |
| Animal Model: | Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice[3]. |
| Dosage: | 0.1, 0.3 mg/kg |
| Administration: | p.o., daily, 21 days, the anti-mTNF-α mAb (250 μg/mouse) was intraperitoneally injected on days 7 and 21. |
| Result: | Increased body weight from day 15 comparable to anti-mTNF-α mAb-treated groups. Clinical scores in the 0.1 and 0.3 mg/kg treated groups were 1.1 and 0.6 and anti-mTNF-α mAb-treated group was 1.2. Inhibited the development of chronic colitis with an efficacy comparable to that of an anti-mTNF-α mAb (250 μg/mouse). |
| Animal Model: | Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice[3]. |
| Dosage: | 0.3 mg/kg |
| Administration: | p.o., daily, 3-4 weeks |
| Result: | Significantly reduced the number of infiltrating lymphocytes and CD4+ T cells. Decreased the number of IFN-γ- and IL-17-producing CD4+ T cells in the lamina propria. Produced significantly less IFN-γ and IL-17 than those from vehicle-treated mice. |
| Animal Model: | MRL/lpr mice at 8 weeks of age without proteinuria[4]. |
| Dosage: | 0.1, 0.3, 1 mg/kg |
| Administration: | p.o., daily, 18 weeks |
| Result: | No mice treated at doses greater than 0.3 mg/kg developed lupus nephritis during the study period. Reduced this infiltration of T cells into the kidneys. Inhibited the development of lymphadenopathy and splenomegaly. Decreased the number of T cells,CD4 T cells, B cells, and MRL/lpr-mouse-specific abnormal T cells. |
| Animal Model: | NZBWF1 mice at 30 weeks of age without proteinuria[4]. |
| Dosage: | 0.1, 0.3 mg/kg |
| Administration: | p.o., daily, 10 weeks |
| Result: | Mean proteinuria scores remained lower than those in the control group. Attenuated the severity of several histological changes including mesangial expansion, glomerular sclerosis, and interstitial infiltrates. |
| Animal Model: | NZBWF1 mice at 41 weeks of age without proteinuria[4]. |
| Dosage: | 0.3 mg/kg |
| Administration: | p.o., daily, 13 weeks |
| Result: | Reduced the number of infiltrating T cells, CD4 T cells, CD8 T cells, and CD4-CD8- double-negative (DN) T cells. Decreased B cell counts. |
References
[1] Sugahara K, et al., Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15-27. DOI:10.1111/bph.13641
[2] Kappos L, et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59. DOI:10.1016/S1474-4422(16)30192-2
[3] Shimano K, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. PLoS One. 2019 Dec 5;14(12):e0226154. DOI:10.1371/journal.pone.0226154
[4] Sugahara K, et al. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. J Immunol Res. 2019 Dec 23;2019:5821589. DOI:10.1155/2019/5821589
[2] Kappos L, et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59. DOI:10.1016/S1474-4422(16)30192-2
[3] Shimano K, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. PLoS One. 2019 Dec 5;14(12):e0226154. DOI:10.1371/journal.pone.0226154
[4] Sugahara K, et al. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. J Immunol Res. 2019 Dec 23;2019:5821589. DOI:10.1155/2019/5821589
Supplier
Chembest Research Laboratories Limited
Telephone021-20908456
Websitehttp://www.BioChemBest.com
Sichuan Wei Keqi Biological Technology Co., Ltd.
Telephone028-81700200 18116577057
Websitehttps://www.weikeqi-biotech.com/
Shanghai Lollane Biological Technology Co.,Ltd.
Telephone021-52996696，15000506266 15000506266
Websitehttp://www.bioll.com
Shanghai Synchem Pharma Co., ltd
Telephone21-619849051-1 18521059765
Websitehttp://www.synchem-pharma.com
Hubei Chuangliankangcheng Pharmaceutical Co., Ltd.
Telephone027-65388397 18164111589
Websitehttp://www.hbclkc.com
Shanghai Changyan Chem & Tech Co., Ltd.
Telephone021-20242659 18930833303
Websitehttp://www.changyanchem.cn
Amadis Chemical Company Limited
Telephone571-89925085
Websitehttp://www.amadischem.com
Medi-tech Bioscientific Co., Ltd.
Telephone0519-83246372 13585352506
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList19938/0_EN.htm
3A Chemicals
Telephone400-668-9898
Websitehttp://www.3achem.com
Zhejiang J&C Biological Technology Co.,Limited
Telephone+1-2135480471 +1-2135480471;
Websitehttps://www.sarms4muscle.com
Hong Kong Tiansheng New Material Trading Co., Ltd
Telephone +8617320695765
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList114554/0_EN.htm
career henan chemical co
Telephone+86-0371-86658258 +8613203830695
Websitehttp://www.coreychem.com
Shanghai Jinyin Biological Technology Co., Ltd
Telephone021-20986266 18019349802
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList1224855/0_EN.htm
https://hanhongsci.com/
Telephone021-54306202 18917919676
Websitehttps://www.hanhongsci.com/
TargetMol Chemicals Inc.
Telephone 15002134094
Websitehttps://www.targetmol.cn/
Ningbo Chaoming Biotechnology Co., Ltd
Telephone 13301662590
Website
Absin Bioscience Inc.
Telephone 13761418683
Websitehttps://www.absin.cn/
Zibo Hangyu Biotechnology Development Co., Ltd
Telephone+86-0533-2185556 +8615965530500
Websitehttps://www.chemicalbook.com/manufacturer/hangyu-chemical-25178/
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine